Viking Therapeutics (VKTX) stock ripped higher on Sept. 22 after the biotech firm disclosed positive top-line results from its Phase 2 trial involving its lead dual GLP-1/GIP agonist — VK2735. The study showed up to 22% placebo-adjusted weight loss at 33 weeks and confirmed the viability of flexible monthly and biweekly dosing. Following today's surge, Viking Therapeutics stock is up roughly 8% versus the start of this year, but down the same from its July high.
SpaceX Has Huge, Unusual Put Options Volume - Is SPCX Set to Fall or Rise From Here? Lucid Just Struck a Partnership With Bolt on Mobility. What This Means for LCID Stock.
Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. The newly released data from the VK2735-102 maintenance study marks a significant de-risking milestone for Viking Therapeutics shares. In the Phase 2 trial, participants transitioned to less frequent maintenance scheduled after an initial 21-week induction period where they lost up to 19% of their body weight.
According to VKTX, its candidate maintained up to 97% of weight loss with every-other-week administration and up to 90% with monthly dosing, offering an attractive, flexible treatment cadence for long-term adherence. Plus, the biotech firm highlighted a clean safety and tolerability profile as well, which strengthens its competitive posture against existing winners (Zepbound and Wegovy) of the rapidly expanding obesity market. While today's rally reflects newfound confidence in Viking's clinical pipeline, prospective investors must weigh both the potential upside and ongoing commercial risks.
On the plus side, VK2735 continues to demonstrate best-in-class efficacy and a favorable safety profile, positioning the company as a prime partner or acquisition target in the multi-billion-dollar weight-loss market. However, buying into today's strength carries tactical risks. Viking remains a clinical-stage biotech without commercialized product revenue, facing long-term capital requirements for Phase 3 trials and intense competition from established pharma giants.
Therefore, dollar cost averaging or waiting for a pullback may offer a safer entry into VKTX shares for risk-tolerant, long-term investors. It's also worth mentioning that Wall Street analysts remain bullish as ever on VKTX stock for the longer term. The consensus rating on Viking Therapeutics remains at "Strong Buy," with the mean price target of about $110 indicating potential for a nearly 200% rally from here.
Extract — continue reading at the source.
